A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate

Trial Profile

A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs ALKS 8700 (Primary) ; Dimethyl fumarate
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms EVOLVE-2; EVOLVE-MS
  • Sponsors Alkermes plc
  • Most Recent Events

    • 16 Mar 2017 Status changed from planning to recruiting, according to an Alkermes media release.
    • 16 Dec 2015 Alkermes plans to submit the NDA for ALKS 8700 to the FDA in 2018, according to a company media release.
    • 29 Nov 2015 The company expects to initiate this trial in mid-2016, according to an Alkermes media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top